Online telehealth company Hims and Hers Health is launching its weight-loss membership and treatment plans in the United ...
Hims & Hers Health ($HIMS) stock recently earned a new Buy rating from Barclays at a price target of $48. Barclays sees ...
Zacks Investment Research on MSN
Hims & Hers plunges 29.1% in 6 months: Time to hold the stock or sell?
Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term losses from the stock lately, despite its ...
Hims & Hers Health stock has seen its fair value estimate trimmed from about $46.00 to roughly $44.36 per share, even as analysts grow more optimistic about its long term revenue trajectory. Stronger ...
The telehealth company Hims & Hers Health is accelerating its international growth strategy, with a new launch in the United Kingdom marking its latest move. This follows closely on the heels of its ...
Hims & Hers Health has sold off ~40% GLP-1 turbulence, but the core growth story remains intact. Read why HIMS stock is a ...
Delving into the details, we found 53% of traders were bullish, while 30% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $373,316, and 7 were calls, valued ...
HIMS expands its tech-driven care with new diagnostics, hormonal treatments, and a Canada launch via Livewell.
Investing.com -- Hims Hers Health Inc (NYSE:HIMS) stock fell 4.4% Wednesday after U.S. lawmakers introduced legislation that could significantly impact the company’s fastest-growing product category.
Shares of Hims & Hers are trending Thursday morning. The San Francisco-based telehealth company announced an international ...
Hims & Hers Health (HIMS) has entered into an agreement to acquire YourBio Health, a Boston-based maker of capillary whole ...
Almost two-thirds of adults in Canada are overweight or living with obesity, according to the U.S. telehealth company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results